Organoid, Mouse Model, and Biomarker

核心3：类器官、模型系统和生物标志物 这个达纳的类器官、模型系统和生物标志物核心的总体目的- 法伯/哈佛癌症中心卵巢癌SPORE应用是为三个核心服务提供 项目和其他核心。核心将由Alan D 'Andrea博士，Joyce Liu和Neil Horowitz指导。 核心的一个主要特征是我们最近在产生短期卵巢癌类器官方面的进展 接近模拟其来源的肿瘤的培养物（Hill SJ，德克尔B，Roberts EA，Horowitz NS，Muto MG，Worley MJ，Feltmate CM，Nucci MR，Swisher EM，Nguyen H，Yang C，Morizane R， Kochupurakkal B，Do KT，Konstantinopoulos PA，Liu JF，Bonventre JV，Matulonis UA，Shapiro GI，Berkowitz RS，Crum CP，D'Andrea AD. DNA修复抑制剂在短期患者源性肿瘤中的反应预测 卵巢癌的治疗癌症发现2018 Sep 13. pii：CD-18-0474。doi：10.1158/2159-8290.CD-18- 0474.）。核心分为三个目标，涉及1）HGSC组织基础设施的发展 收集，2）使用PDX模型评估体内药物组合，和3）使用HGSC类器官 在体外评估药物组合。核心将提供这些研究，以及相关的DNA修复， 细胞凋亡生物标志物的临床试验者在三个项目。核心将提供1）卵巢癌组织 收集基础设施的参与者在孢子，2）产生和分析短期卵巢 癌类器官培养物，和3）卵巢癌的鼠PDX模型的产生和分析。

PROJECT SUMMARY - Core 3: Organoid, Model Systems, and Biomarkers Core The overall purpose of the Organoids, Model Systems, and Biomarkers Core of this Dana- Farber/Harvard Cancer Center Ovarian Cancer SPORE application is to provide core services to the three projects and to the other cores. The core will be directed by Drs. Alan D’Andrea, Joyce Liu, and Neil Horowitz. A primary feature of the core is our recent advances in the generation of short-term ovarian cancer organoid cultures which closely mimic the tumor from which they are derived (Hill SJ, Decker B, Roberts EA, Horowitz NS, Muto MG, Worley MJ, Feltmate CM, Nucci MR, Swisher EM, Nguyen H, Yang C, Morizane R, Kochupurakkal B, Do KT, Konstantinopoulos PA, Liu JF, Bonventre JV, Matulonis UA, Shapiro GI, Berkowitz RS, Crum CP, D’Andrea AD. Prediction of DNA Repair Inhibitor Response in Short Term Patient-derived Ovarian Cancer Organoids. Cancer Discov. 2018 Sep 13. pii: CD-18-0474. doi: 10.1158/2159-8290.CD-18- 0474.). The core is divided into three aims pertaining to 1) the development of infrastructure from HGSC tissue collection, 2) the use of PDX models to assess drug combinations in vivo, and 3) the use of HGSC organoids to assess drug combinations in vitro. The core will provide these studies, as well as relevant DNA repair and apoptosis biomarkers to the clinical trialists in the thee projects. The core will provide 1) ovarian cancer tissue collection infrastructure for participants in the SPORE, 2) the generation and analysis of short-term ovarian cancer organoid cultures, and 3) the generation and analysis of murine PDX models of ovarian cancer.